CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
H.C. Wainwright initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $20 price target Actuate is a clinical-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback